MCM
DGX icon

Maple Capital Management’s Quest Diagnostics DGX Stock Holding History

Maple Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$453K Sell
2,313
-757
-25% -$147K 0.03% 77
2025
Q4 		$533K Buy
+3,070
New +$559K 0.03% 73

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Maple Capital Management's DGX Position: Q1 2026 in Review

Maple Capital Management reduced its Quest Diagnostics (DGX) stake by 25% in Q1 2026, selling an estimated $147K and leaving 2,313 shares worth $453K. The position accounts for 0.03% of the portfolio, ranked #77.

Maple Capital Management first reported a position in DGX in Q4 2025 and has held it in 2 quarters since. The position peaked at $533K in Q4 2025. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Maple Capital Management held 2,313 shares of Quest Diagnostics worth $453K as of Q1 2026.
  • Maple Capital Management sold 757 Quest Diagnostics shares in Q1 2026, an estimated $147K.
  • Quest Diagnostics made up 0.03% of Maple Capital Management's portfolio in Q1 2026, its #77 holding.
  • Maple Capital Management first reported a position in Quest Diagnostics in Q4 2025 and has held it in 2 quarters since.
  • Maple Capital Management's Quest Diagnostics position peaked at $533K in Q4 2025.
  • 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Maple Capital Management's 13F filing for Q1 2026, filed 8 May 2026.